Holen Sie sich die Stockscreener-App
35.32
0.51%
-0.18
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$35.50
Offen:
$35.79
24-Stunden-Volumen:
976.11K
Relative Volume:
0.63
Marktkapitalisierung:
$5.74B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$333.35M
KGV:
18.11
EPS:
1.95
Netto-Cashflow:
$315.22M
1W Leistung:
-1.59%
1M Leistung:
+17.34%
6M Leistung:
+24.98%
1J Leistung:
+21.04%
1-Tages-Spanne:
$35.09
$35.79
1-Wochen-Bereich:
$35.09
$36.45
52-Wochen-Spanne:
$22.90
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Vergleichen Sie ALKS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
35.32 | 5.74B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-11-05 | Hochstufung | Stifel | Hold → Buy |
| 2024-06-17 | Eingeleitet | TD Cowen | Buy |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-20 | Herabstufung | UBS | Neutral → Sell |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Eingeleitet | UBS | Neutral |
| 2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
| 2022-04-22 | Fortgesetzt | Goldman | Buy |
| 2022-04-20 | Eingeleitet | Goldman | Buy |
| 2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Eingeleitet | Citigroup | Neutral |
| 2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
| 2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
Hussman Strategic Advisors Inc. Invests $1.93 Million in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes plc (NASDAQ:ALKS) Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Alkermes plc VP Samuel Joseph Parisi sells $47,360 in stock By Investing.com - Investing.com South Africa
Alkermes plc VP Samuel Joseph Parisi sells $47,360 in stock - Investing.com India
Van ECK Associates Corp Acquires 32,581 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes (NASDAQ:ALKS) Hits New 12-Month HighWhat's Next? - MarketBeat
Craig C. Hopkinson Sells 144,419 Shares of Alkermes plc (NASDAQ:ALKS) Stock - MarketBeat
Alkermes (NASDAQ:ALKS) Price Target Raised to $32.00 - MarketBeat
Opioid Use Disorder Treatment Market Size in the 7MM was around - openPR
Vontobel Holding Ltd. Sells 7,982 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes (NASDAQ:ALKS) Receives "Neutral" Rating from HC Wainwright - MarketBeat
Alkermes (NASDAQ:ALKS) Rating Increased to Strong-Buy at StockNews.com - MarketBeat
HC Wainwright Issues Negative Estimate for Alkermes Earnings - MarketBeat
Alkermes (NASDAQ:ALKS) Announces Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat
Alkermes (NASDAQ:ALKS) Updates FY 2025 Earnings Guidance - MarketBeat
Alkermes Plc EPS Soars Past Forecasts - AOL
Alkermes plc Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next - Yahoo Finance
How to Take Advantage of moves in (ALKS) - Stock Traders Daily
Alkermes targets $310M-$340M adjusted EBITDA amid LYBALVI growth and orexin pipeline expansion - MSN
Alkermes (NASDAQ:ALKS) Earns Buy Rating from Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
Alkermes plc. Officer Sells Shares Worth Over $11 Million - TradingView
Earnings call transcript: Alkermes Q4 2024 beats EPS forecasts, stock rises - MSN
Alkermes Reaches Analyst Target Price - Nasdaq
Regulatory Challenges Pose Significant Risks to Alkermes’ Financial Stability - TipRanks
Alkermes plc Reports Record Revenues in 2024 Earnings Call - TipRanks
Alkermes price target raised to $32 from $30 at Goldman Sachs - TipRanks
Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up - MSN
Alkermes Shares Climb Amid Strong Earnings and Growth Prospects - TipRanks
Alkermes (NASDAQ:ALKS) Sets New 1-Year High on Earnings Beat - MarketBeat
Alkermes outlook reflects underlying strength, says H.C. Wainwright - TipRanks
Alkermes plc (NASDAQ:ALKS) Q4 2024 Earnings Call Transcript - Insider Monkey
Alkermes PLC (ALKS) Q4 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
Alkermes PLC (ALKS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Debt-Free Milestone - Yahoo Finance
Alkermes Plc earnings beat by $0.30, revenue topped estimates - Investing.com Nigeria
Alkermes plc Reports Strong 2024 Financial Results - TipRanks
Alkermes: Q4 Earnings Snapshot - Midland Daily News
Alkermes plc (ALKS) reports earnings - Quartz
Alkermes plc. SEC 10-K Report - TradingView
Alkermes plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Alkermes (ALKS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Alkermes plc Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Alkermes (ALKS) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alkermes Plc-Aktie (ALKS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Feb 13 '25 |
Option Exercise |
30.12 |
144,419 |
4,350,097 |
202,294 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Feb 12 '25 |
Option Exercise |
19.64 |
199,196 |
3,912,871 |
262,796 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Feb 12 '25 |
Sale |
32.78 |
204,921 |
6,718,278 |
57,875 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Feb 13 '25 |
Sale |
35.53 |
144,419 |
5,130,698 |
57,875 |
0.99%
3.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):